HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.

Abstract
Infiltrating astrocytomas and oligoastrocytomas of low to anaplastic grade (WHO grades II and III), in spite of being associated with a wide range of clinical outcomes, can be difficult to subclassify and grade by the current histopathologic criteria. Unlike oligodendrogliomas and anaplastic oligodendrogliomas that can be identified by the 1p/19q codeletion and the more malignant glioblastomas (WHO grade IV astrocytomas) that can be diagnosed solely based on objective features on routine hematoxylin and eosin sections, no such objective criteria exist for the subclassification of grade II-III astrocytomas and oligoastrocytomas (A+OA II-III). In this study, we evaluated the prognostic and predictive value of the stem cell marker nestin in adult A+OA II-III (n = 50) using immunohistochemistry and computer-assisted analysis on tissue microarrays. In addition, the correlation between nestin mRNA level and total survival was analyzed in the NCI Rembrandt database. The results showed that high nestin expression is a strong adverse prognostic factor for total survival (p = 0.0004). The strength of the correlation was comparable to but independent of the isocitrate dehydrogenase 1/2 (IDH 1/2) mutation status. Histopathological grading and subclassification did not correlate significantly with outcome, although the interpretation of this finding is limited by the fact that grade III tumors were treated more aggressively than grade II tumors. These results suggest that nestin level and IDH 1/2 mutation status are strong prognostic features in A+OA II-III and possibly more helpful for treatment planning than routine histopathological variables such as oligodendroglial component (astrocytoma vs. oligoastrocytoma) and WHO grade (grade II vs. III).
AuthorsKimmo J Hatanpaa, Tianshen Hu, Vamsidhara Vemireddy, Chan Foong, Jack M Raisanen, Dwight Oliver, Matthew C Hiemenz, Dennis K Burns, Charles L White 3rd, L Anthony Whitworth, Bruce Mickey, Martha Stegner, Amyn A Habib, Karen Fink, Elizabeth A Maher, Robert M Bachoo
JournalJournal of neuro-oncology (J Neurooncol) Vol. 117 Issue 1 Pg. 183-189 (Mar 2014) ISSN: 1573-7373 [Electronic] United States
PMID24519516 (Publication Type: Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • NES protein, human
  • Nestin
  • RNA, Messenger
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
Topics
  • Adult
  • Aged
  • Astrocytoma (diagnosis, genetics, metabolism, pathology)
  • Biomarkers (metabolism)
  • Brain Neoplasms (diagnosis, genetics, metabolism, pathology)
  • Female
  • Follow-Up Studies
  • Glioma (diagnosis, genetics, metabolism, pathology)
  • Humans
  • Isocitrate Dehydrogenase (genetics)
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Nestin (metabolism)
  • Prognosis
  • RNA, Messenger (metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: